tetano
Editor, Senior Moderator
Vaccine. 2018 Apr 5. pii: S0264-410X(18)30262-7. doi: 10.1016/j.vaccine.2018.02.075. [Epub ahead of print]
[h=1]Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.[/h] Lapuente D[SUP]1[/SUP], Ruzsics Z[SUP]2[/SUP], Thirion C[SUP]3[/SUP], Tenbusch M[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Since preexisting immunity and enhanced infection rates in a clinical trial of an HIV vaccine have raised some concerns on adenovirus (Ad) serotype 5-based vaccines, we evaluated the subgroup D adenovirus serotype Ad19a for its suitability as novel viral vector vaccine against mucosal infections. In BALB/c mice, we compared the immunogenicity and efficacy of E1/E3-deleted Ad19a vectors encoding the influenza A virus (IAV)-derived antigens hemagglutinin (HA) and nucleoprotein (NP) to the most commonly used Ad5 vectors. The adenoviral vectors were applied intranasally and induced detectable antigen-specific T cell responses in the lung and in the spleen as well as robust antibody responses. A prior DNA immunization significantly improved the immunogenicity of both vectors and resulted in full protection against a lethal infection with a heterologous H3N2 virus. Nevertheless, the Ad5-based vectors were slightly superior in reducing viral replication in the lung which corresponded to higher NP-specific T cell responses measured in the lungs.
[h=4]KEYWORDS:[/h] Ad19a; Ad5; Adenoviral vectors; Influenza A virus; Mucosal vaccines
PMID: 29628150 DOI: 10.1016/j.vaccine.2018.02.075
[h=1]Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.[/h] Lapuente D[SUP]1[/SUP], Ruzsics Z[SUP]2[/SUP], Thirion C[SUP]3[/SUP], Tenbusch M[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Since preexisting immunity and enhanced infection rates in a clinical trial of an HIV vaccine have raised some concerns on adenovirus (Ad) serotype 5-based vaccines, we evaluated the subgroup D adenovirus serotype Ad19a for its suitability as novel viral vector vaccine against mucosal infections. In BALB/c mice, we compared the immunogenicity and efficacy of E1/E3-deleted Ad19a vectors encoding the influenza A virus (IAV)-derived antigens hemagglutinin (HA) and nucleoprotein (NP) to the most commonly used Ad5 vectors. The adenoviral vectors were applied intranasally and induced detectable antigen-specific T cell responses in the lung and in the spleen as well as robust antibody responses. A prior DNA immunization significantly improved the immunogenicity of both vectors and resulted in full protection against a lethal infection with a heterologous H3N2 virus. Nevertheless, the Ad5-based vectors were slightly superior in reducing viral replication in the lung which corresponded to higher NP-specific T cell responses measured in the lungs.
[h=4]KEYWORDS:[/h] Ad19a; Ad5; Adenoviral vectors; Influenza A virus; Mucosal vaccines
PMID: 29628150 DOI: 10.1016/j.vaccine.2018.02.075